Abstract
The pyrazole heterocycle displayed versatile pharmacological activity ranging from anti-inflammatory to antiviral. Herein, we report the synthesis of bis-pyrazole as receptor- interacting protein 1 kinase inhibitor and evaluated for antiproliferative activity against pancreatic cancer line, PANC-1. Among twelve compounds, three candidates displayed the cytotoxicity IC50 value in single digit micromolar concentration. From the preliminary evaluation, the compound 31 emerged as a potential inhibitor with an IC50 = 4.1 µM. The lead compound showed similar inhibitor IC50 value in comparison to the positive control, doxorubicin. The docking studies confirm that these analogs may require further investigation to improve the potency.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.